Published November 2019
| public
Journal Article
Alternative mRNA splicing in cancer immunotherapy
- Creators
- Frankiw, Luke
-
Baltimore, David
-
Li, Guideng
Abstract
Immunotherapies are yielding effective treatments for several previously untreatable cancers. Still, the identification of suitable antigens specific to the tumour that can be targets for cancer vaccines and T cell therapies is a challenge. Alternative processing of mRNA, a phenomenon that has been shown to alter the proteomic diversity of many cancers, may offer the potential of a broadened target space. Here, we discuss the promise of analysing mRNA processing events in cancer cells, with an emphasis on mRNA splicing, for the identification of potential new targets for cancer immunotherapy. Further, we highlight the challenges that must be overcome for this new avenue to have clinical applicability.
Additional Information
© 2019 Springer Nature Publishing AG. Accepted 02 July 2019; Published 30 July 2019. Preparation of this review was supported by an endowment provided by the Raymond and Beverly Sackler Foundation, the Parker Institute for Cancer Immunotherapy and the National Cancer Institute (grant 1U54 CA199090-01). Author Contributions: The authors contributed equally to all aspects of the article. The authors declare no competing interests.Additional details
- Eprint ID
- 97508
- DOI
- 10.1038/s41577-019-0195-7
- Resolver ID
- CaltechAUTHORS:20190730-084832126
- Raymond and Beverly Sackler Foundation
- Parker Institute for Cancer Immunotherapy
- 1U54 CA199090-01
- NIH
- National Cancer Institute
- Created
-
2019-07-30Created from EPrint's datestamp field
- Updated
-
2021-11-16Created from EPrint's last_modified field